Payam Javan: In a monumental win for the American people, President Donald Trump announced a groundbreaking agreement on Friday, forcing nine of the world’s largest drug manufacturers to drastically cut prices on their flagship medications. This isn’t just a political talking point; it’s a promise delivered, ensuring that starting next year, American drug prices will plummet, becoming the lowest in the developed world. For too long, patriotic Americans have been fleeced, paying nearly three times more than other nations, effectively subsidizing globalist socialist schemes while our own citizens struggled. This historic move by President Trump is a direct challenge to the corrupt system that has enriched Big Pharma at the expense of hardworking families, proving once again that he is a true champion for the forgotten men and women of this nation.
This isn’t just about lower prices; it’s about putting America First in every sense. Under these revolutionary agreements, companies like Merck, Gilead, and Novartis will adopt “most-favored-nation” pricing, matching the lowest prices offered anywhere in the world for new U.S. drug launches. But the brilliance of President Trump’s deal goes further: in exchange for these price cuts, companies receive a three-year exemption from tariffs, provided they invest heavily in U.S. manufacturing. As Commerce Secretary Howard Lutnik emphasized, this is a powerful one-two punch that brings jobs home, boosts our economy, and ensures our life-saving drugs are made right here in America, under the watchful eye of the FDA, guaranteeing safety and quality. This is true economic nationalism in action, securing our supply chains and our future.
This victory is a direct reversal of the disastrous trends seen before President Trump took office, where drug prices soared by 25%. Dr. Mehmet Oz, administrator for the Centers for Medicare and Medicaid Services, rightly pointed out that Americans will now finally be able to afford the medications they need to live healthy, productive lives. Merck’s commitment to offering diabetes drugs like Januvia at a whopping 70% off list prices through TrumpRx.gov is just one example of the tangible benefits. This is what real leadership looks like: cutting through the bureaucratic red tape and the special interest lobbying to deliver tangible results for the citizens who elected him, something the mainstream media would rather you ignore.
President Trump’s unwavering resolve to tackle Big Pharma’s egregious practices has been consistent, building on previous agreements with Eli Lilly and Novo Nordisk, and cemented by his May 2025 directive on “Most-Favored-Nation Prescription Drug Pricing.” He has tirelessly fought against the globalist agenda that saw American taxpayers subsidizing the healthcare of other nations with exorbitant prices at home. This latest triumph is a testament to his
